Immatics (IMTX) Common Equity (2019 - 2025)
Immatics (IMTX) posted Common Equity of $563.5 million for Q4 2025, up 15.68% sequentially from $487.1 million in Q3 2025, and down 8.26% YoY from $614.3 million in Q4 2024.
Immatics (IMTX) Common Equity (2019 - 2025) Analysis & Trends
Immatics has reported Common Equity for 7 years, with the latest figure at $563.5 million in Q4 2025.
- Quarterly Common Equity fell 8.26% year-over-year to $563.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $563.5 million (down 8.26% YoY) and the FY2025 annual result came in at $546.9 million, down 12.09% from the prior year.
- Common Equity rose to $563.5 million in Q4 2025 per IMTX's latest filing, from $487.1 million in the prior quarter.
- Over five years, Common Equity peaked at $614.3 million in Q4 2024 and troughed at $27.5 million in Q4 2021.
- A 5-year average of $288.9 million and a median of $235.9 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2022: Common Equity tumbled 95.71% in 2021, then jumped 653.69% in 2022.
- Over 5 years, Common Equity stood at $27.5 million in 2021, then surged by 653.69% to $207.5 million in 2022, then grew by 12.86% to $234.1 million in 2023, then soared by 162.35% to $614.3 million in 2024, then dropped by 8.26% to $563.5 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $563.5 million, $487.1 million, and $525.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 563.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 563.51 Mn |
| Sep 30, 2025 | 487.12 Mn |
| Jun 30, 2025 | 525.88 Mn |
| Mar 31, 2025 | 564.45 Mn |
| Dec 31, 2024 | 614.27 Mn |
| Sep 30, 2024 | 416.41 Mn |
| Jun 30, 2024 | 410.58 Mn |
| Mar 31, 2024 | 428.17 Mn |
| Dec 31, 2023 | 234.14 Mn |
| Sep 30, 2023 | 269.70 Mn |
| Jun 30, 2023 | 237.62 Mn |
| Mar 31, 2023 | 214.76 Mn |
| Dec 31, 2022 | 207.47 Mn |
| Sep 30, 2022 | 113.98 Mn |
| Jun 30, 2022 | 133.32 Mn |
| Mar 31, 2022 | 130.18 Mn |
| Dec 31, 2021 | 27.53 Mn |
| Sep 30, 2021 | 41.46 Mn |
| Jun 30, 2021 | 67.00 Mn |
| Mar 31, 2021 | 91.20 Mn |